Welcome to Rinri

Founded in 2018, Rinri Therapeutics Ltd. is a therapeutic discovery and development company working in the field of hearing loss supported by Boehringer Ingelheim Venture Fund and UCB Ventures, BioCity and The University of Sheffield.

Rinri Therapeutics has been founded on pioneering research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield.

The Company has a team of experienced management, strong academic pedigree and excellent potential for clinical development.

Hearing Loss
Auditory neuropathy

Our Technology

Rinri’s lead therapeutic candidate is Rincell-1. It is a novel stem cell product and a first-in-class regenerative cell therapy that seeks to reverse auditory neuropathy, a form of sensorineural hearing loss specifically affecting the transmission of nerve signals from the inner ear to the auditory centres of the brain.

Our Technology

Rinri’s lead therapeutic candidate is Rincell-1. It is a novel stem cell product and a first-in-class regenerative cell therapy that seeks to reverse auditory neuropathy, a form of sensorineural hearing loss specifically affecting the transmission of nerve signals from the inner ear to the auditory centres of the brain.

Our Therapy Area

Patients with sensorineural hearing loss, and their families, are at the heart of our work here at Rinri. We are developing an innovative and life-changing cell therapy, and bringing it from the laboratory to patients, to address a large and unmet clinical need.

Our Team